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Figure 2: Change in FibroScan values as a function of treatment. The upper graph plots the initial and
subsequent FibroScan result for patients who were not treated or who were treated and achieved viral
clearance (Sustained Viral Response (SVR)). The lower graph is a plot of the improvement in FibroScan
value. Using pair wise analysis, the patients who achieved an SVR has a significant improvement (p<0.005)
while those who were not treated did not.

Non-African Americans
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Figure 1: APRI and FIB-4 Scores as compared to FibroScan scores for the patients with cirrhosis (kPa >12.5).
The green line represents the literature cut-off typically used to identify patients with significant
fibrosis/cirrhosis by the serum-based assays. The primary advantage of FibroScan is in identifying
patients with early cirrhosis where the serum assessment has the lowest sensitivity and specificity.

In patients who had FibroScan-defined cirrhosis, neither their APRI nor FIB4 scores were as reliable as FibroScan for identifying patients with cirrhosis
(Figure 1). The data in Figure 1 plots the FibroScan score vs the two serum
assessment values as continuous variables. The primary failure to identify
cirrhosis was due to low serum-based scores in patients who had early
cirrhosis as defined by FibroScan.
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•

APRI

APRI= ((AST value /AST upper limit)/Platelet Count) x 100
FIB-4= (Age(years) x AST)/(Platelet Count x Sqrt(ALT))

Change in Repeat FibroScan Value by Treatment (SVR) vs No Treatment
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METHODS

• Of 332 individuals with a FibroScan evaluation of
fibrosis between 2014 and 2016, 79 (24%) had a
score of >12.5 kPa (cirrhosis). Their electronic
medical records were reviewed, risk factor for
cirrhosis determined and outcomes evaluated.
• Data analysis was performed using the SAS-JMP
statistical software.
• Serum based fibrosis was calculated using the
AST to Platelet Ratio Index (APRI) and Fibrosis4 (FIB-4) within a year of the FibroScan. An
APRI score >0.7 and FIB-4 score >3.25 was used
for predicting advanced fibrosis/cirrhosis.

Outcomes for patients with HCV were tracked using two criteria:
a) improvement in FibroScan scores, and
b) development of decompensated cirrhosis.

Correlation between FibroScan Fibrosis and Serum Fibrosis Value

APRI

• Identifying patients with cirrhosis is
complicated, but Ultrasound based Transient
Elastography (TE;FibroScan) for non-invasive
assessment of fibrosis may offer a more
accurate approach than serum-based cirrhosis
determination.
• The objective of our study was to use a
FibroScan database to identify patients with
cirrhosis in our primarily African American
(AA) Hepatitis C (HCV) patients.
• Cirrhotic patients were used to compare
FibroScan to serum assessments of fibrosis
and to track outcomes for HCV patients.

Patient Population
Cirrhotic HCV patients were 92% AA and 52% male. FibroScan
values ranged from 12.5 to 75 with a mean of 25.5 kPa for AA and
28.0 kPa for Non-AA. Most HCV patients (82%) were treated after
their initial FibroScan with a high sustained virologic response (SVR)
rate (97%).

RESULTS
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INTRODUCTION

Patients with a subsequent FibroScan after HCV eradication, had a
statistically significant improvement in fibrosis if they achieved
SVR as compared to the non-treated patients (p<0.005) (Figure 2).
Only 1 patient developed decompensation in the SVR group (1/40=
3%) as compared to non responders or not treated patients (3/5=
60%; p<0.0001)

CONCLUSIONS
• FibroScan is better than serum-based assays for
identifying early cirrhosis in HCV patients.
• Identifying regression of cirrhosis scores after HCV
eradication is also a potential utility for the methodology.
• Regression of cirrhosis may predict decreased risk for
decompensation, hepatocellular carcinoma and
esophageal varices.
• Further studies evaluating the relationship between
improvement in Fibrosis by FibroScan and the
development of liver disease are needed.

